Whole cell or outer membrane vesicles (OMVs) are an attractive vaccine platform for Gram-negative bacteria that do not have a single protective vaccine target due to their capacity to display multiple antigens correctly on the bacterial surface. The development of effective gonococcal whole cell or OMV vaccines, however, is challenged by gonococcal-mediated immunosuppression of the adaptive immune response. While the use of Th1 cell-inducing adjuvants can relieve this immunosuppression, here we tested the potential of the genetically related bacterium Snodgrassella alvi, a honeybee gut commensal, as a protective gonorrhea vaccine. Comparison of the genome sequences of S. alvi strain MMP18 with two different N. gonorrhoeae strains showed a 59% identity, with numerous predicted proteins having a high degree of amino acid homology, including several leading vaccine targets. In support of the hypothesis that S. alvi induces protective immune responses against N. gonorrhoeae, we demonstrated that vaccination of mice with S. alvi induced cross-reactive humoral and cellular immune responses. High serum and vaginal IgG antibody titers were detected against Ng OMVs by ELISA and several gonococcal outer membrane proteins were recognized by western blot. S. alvi also induced a serum bactericidal antibody response (cidal50 titers: 1:16, 500 against N. gonorrhoeae strains F62 and FA1090, respectively). Splenic TNF-α+ CD4+ T cells and IFN-γ+ CD4+ T cells from vaccinated mice were significantly elevated in response to heat-killed S. alvi or heat-killed N. gonorrhoeae when compared to unimmunized (naive) splenic CD4+ T cells, and a modest increase in Th17+ CD4+ T cells was observed. To test whether protection could be induced by S. alvi vaccination, we immunized mice intraperitoneally with S. alvi without added adjuvant and challenged them with N. gonorrhoeae. Vaccinated mice cleared infection significantly faster compared to unvaccinated controls, with 50% of vaccinated mice clearing infection by day 3-post challenge and only 12.5% colonized with N. gonorrhoeae on day 7 post-challenge, compared to 83% of control mice. We conclude S. alvi vaccination provides significant protection against N. gonorrhoeae without requiring an adjuvanted formulation, and that further development of an S. alvi-based gonorrhea vaccine is warranted.